Nasdaq
$31.00▼ 0.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.72BShares out 55.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
33- 10.16After-hours26.10.17 05:058-KKey event#●●●#●●●
Maze Therapeutics, Inc.
Maze Therapeutics entered into an exchange agreement on October 15, 2026, with Frazier Life Sciences entities. The company exchanged 2,776,007 shares of its common stock for pre-funded warrants to purchase an equivalent number of shares at an exercise price of $0.001 per share. Following this transaction, the company's total outstanding common stock as of October 16, 2026, is 53,931,889 shares.…more
$31.00-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:124Ownership
Maze Therapeutics, Inc.
Insider Jason V. Coloma of Maze Therapeutics, Inc. filed a Form 4 report on October 2, 2026, regarding changes in beneficial ownership of securities as of October 1, 2026. This filing serves as the official disclosure of the insider's equity position.…more
$31.00-0.03%vs prev closeView filingShare - 10.2After-hours26.10.03 05:094Ownership
Maze Therapeutics, Inc.
Insider Bernstein Harold filed a Form 4 report on October 1, 2026, regarding their beneficial ownership of Maze Therapeutics, Inc. securities. This filing serves to officially disclose changes in the insider's equity holdings.…more
$31.00-0.03%vs prev closeView filingShare
32 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6After-hours26.10.07 05:06#●●●#●●●
Maze Therapeutics to Present Updated Phase 2 MZE829 Data
Maze Therapeutics will present updated Phase 2 data for its kidney disease drug candidate MZE829 at the ASN Kidney Week on October 24. The presentation will provide the latest clinical insights regarding the efficacy and safety of the treatment.…more
$31.00-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.13After-hours26.08.14 05:42
●●●●●●●● ●●●●● ●●●●●●
Maze Therapeutics has appointed clinical and biopharmaceutical industry experts Dr. Paula Johnson and Dr. Sophie Kornowski to its Board of Directors. The company aims to leverage their expertise to advance its clinical pipeline and pre-commercial planning.…more
$31.00-0.03%vs prev close - 8.11After-hours26.08.12 05:01
●●●●●●●● ●●●●● ●●●●●●
메이즈 테라퓨틱스는 주요 파이프라인인 MZE829와 MZE782의 임상 시험이 계획대로 진행 중이라고 밝혔습니다. 약 4억 9,500만 달러의 현금성 자산을 확보해 2029년까지 안정적인 운영 자금을 마련했습니다.…more
$31.00-0.03%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report